Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Journal Title: Chronic Obstructive Pulmonary Disease: Open Access - Year 2017, Vol 2, Issue 1
Abstract
Background: Acute exacerbation (AE) is known as a leading cause of morbidity and mortality in chronic fibrosing group includes idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). There is no standardizes drug therapy with comparative studies. The clinical application of recombinant human soluble thrombomodulin (rhTM) has recently been expected against AE-IPF/NSIP, however, the impact of rhTM remains unestablished. Thus, this review assessed the impact of rhTM on mortality in patients with AE-IPF/NSIP. Methods: PubMED database was investigated for studies in English on May 2017 by two independent reviewers. The investigated period was restricted to previous 10 years. Studies was included adults with AE of IPF or idiopathic interstitial pneumonias, and treatment with thrombomodulin. Key data on study design, patient characteristics, outcome measures and adverse events were extracted for the review. We pooled mortality using random-effects meta-analysis Results: Three prospective and two retrospective studies were included. The five studies recruited a total of 77 patients receiving rhTM treatment (rhTM group). Corticosteroid therapy was examined in all studies for both rhTM groups and non-rhTM group. Mortality at 28 days or one month was evaluated in all three prospective studies, and was significantly lower in the rhTM group than in nonrhTM group. The pooled 1-month mortality was significantly lower in rhTM group (Odds Ratio (OR): 0.25 (95% CI, 0.08-0.77)). Mortality at 3 months was also lower in rhTM group. In patients with AE-IPF/NSIP, rhTM administration was of significant prognostic value of 3-month mortality by univariate analysis and by multivariate analysis. Two retrospective studies reported adverse effect in rhTM group and/or non-rhTM group. Conclusion: In this study, a decline in mortality was confirmed when rhTM was administered in treating AE-IPF/ NSIP, in conjunction with steroid therapy and immunosuppressive drugs. It indicated a possibility of rhTM administration being effective against AE-IPF/NSIP.
Authors and Affiliations
Kenji Tsushima
Keywords
Related Articles
- EP ID EP304124
- DOI 10.21767/2572-5548.100024
- Views 26
- Downloads 0
Relation between Cor Pulmonale Status and Metrics of Six Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease: A Cross Sectional Study
Background: Cor pulmonale is a complication of chronic obstructive pulmonary disease (COPD). The use of the six minute walk test (6MWT) to discriminate between COPD patients with and without cor pulmonale remains unclear...
Minute lesions of alveolar damages in lungs of patients with stable chronic obstructive pulmonary disease
Objective: To reveal the mechanism underlying recruitment of neutrophils in chronic obstructive pulmonary disease (COPD) lungs and to investigate the role of minute lesions of alveolar damage (MLADs) in emphysema develop...
Characterization of Smoking Habits Patterns in Medical Doctors of a Central Hospital in PortugalâÂÂWhat has Changed after 15 Years? A Comparative CrossSectional Study
Introduction: Tobacco dependence remains one of the primary health care concerns worldwide. Attitude of healthcare professionals towards smoking is crucial for any long-term prevention and smoking cessation program. Obj...
Thrombomodulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Background: Acute exacerbation (AE) is known as a leading cause of morbidity and mortality in chronic fibrosing group includes idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). There is n...
COPD Treatment in Real Life and Randomized Controlled Trials: Is There Any Difference between Both Settings?
In the last decade, for treatment of patients with chronic obstructive pulmonary disease (COPD) a myriad of new medications, mostly administered in new inhalation devices were introduced on the market. In addition, All,...